Vancocin-CP [穩可信] - Taiwan - 全球药品采购网

TOP

Vancocin-CP [穩可信]

2014-11-11 20:56:53 来源: 作者: 【大中小】浏览:738次评论:0条

全民健康保險藥品給付規定 / 健保碼及健保價

See related Vancocin-CP[穩可信] information

製造商

Invida

代理/經銷商

Excelsior

成份

Vancomycin HCl

適應症

Cap Treatment of staphylococcal enterocolitis & antibiotic-associated pseudomembranous colitis due to C. difficile. Inj Treatment of staphylococcal endocarditis, bone infections, lower respiratory tract infections, septicemia, soft tissue infections, pseudomembranous colitis due to C. difficile.

用量

Cap Adult 500 mg-2 g/day in 3-4 divided doses for 7-10 days. Children 40 mg/kg/day in 3-4 divided doses for 7-10 days. Max: 2 g/day. IV infusion In adults, concentrations of no more than 5 mg/mL are recommended. In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used. Adult 500 mg 6 hrly or 1 g 12 hrly. Children 10 mg/kg/dose every 6 hr. Neonates & young infants Initially 15 mg/kg, followed by 10 mg/kg every 12 hr in the 1st week of life & every 8 hr thereafter until 1 month of age. Administer each dose over 60 mins.

過量

View Vancocin-CP[穩可信] overdosage for action to be taken in the event of an overdose.

用法

May be taken with or without food

美國食品藥物管理局之懷孕等級



when used parenterally; B when used orally.

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

禁忌

Hypersensitivity.

警告

For additional cautionary notes to warn of the potential risk of using the medicine... click to view Vancocin-CP[穩可信] detailed prescribing infomation

注意事項

Renal impairment, hearing loss, Pseudomembranous colitis, inflammatory disorders of the intestinal mucosa. Pregnancy, lactation. Overgrowth of non-susceptible organisms. Avoid rapid infusion (risk of anaphylactoid reactions).

不良反應

Nephrotoxicity, ototoxicity, reversible neutropenia, thrombocytopenia. Infrequently hypersensitivity reactions, drug fever, chills, nausea, eosinophilia, hypotension, wheezing, dyspnea, urticaria, pruritus, flushes, muscle spasm or pain, rashes (including exfoliative dermatitis), Stevens-Johnson syndrome, toxic epidermal necrolysis & rare cases of vasculitis.
View ADR Monitoring Website[參閱藥物不良反應監測表格]

交互作用

Coadministration of IV vancomycin with anesthetic agents may result in erythema & histamine-like flushing & anaphylactoid reactions. Concurrent or sequential use of other neurotoxic &/or nephrotoxic antibiotics e.g. amphotericin B, aminoglycosides, bacitracin, polymixin B, colistin, viomycin or cisplatin, with IV vancomycin requires careful monitoring.
View more drug interactions with Vancocin-CP[穩可信]

使用上注意

For caution against possible variation of physical aspect of medicine... click to view Vancocin-CP[穩可信] detailed prescribing infomation

儲存

View Vancocin-CP[穩可信] storage conditions for details to ensure optimal shelf-life.

描述

View Vancocin-CP[穩可信] description for details of the chemical structure and excipients (inactive components).

作用

View Vancocin-CP[穩可信] mechanism of action for pharmacodynamics and pharmacokinetics details.

本商品之市售規格

劑型

包裝

圖片